Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-10-18

FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for Neurontin (gabapentin) filed by Parke-Davis Div of Pfizer Inc. The approval concerns a modification to the NDA 0…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NEURONTIN (gabapentin)

Snippet

SUPPL AP for NEURONTIN (GABAPENTIN)